INS and major depressive disorder: The percentages of patients reporting no problems in dimensions of mobility, pain/discomfort and anxiety/depression increased significantly from 84.5% to 91.0% (p < 0.0001), 71.4% to 80.7%(p < 0.0001) and 71.8% to 75.5% (0.0236), respectively, for the prior insulin-experienced group, and from 89.5% to 91.5% (p = 0.0005), 79.1% to 83.4%(p < 0.0001) and 74.9% to 77.5% (p = 0.0028), respectively, for the insulin-naïve group.